All In Biotech

Drug Trial Radar · NCT00558558

Haelan and Nutrition in Cancer Patients

A Phase II Study Examining the Role of Fermented Soy Beverage for Improving Cancer-Associated Anorexia and Cachexia

Last checked: Nov 19, 2026Latest source record: May 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

6

Actual

Start

Oct 2007

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Haelan Products, Inc.
First posted
Nov 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary: * To determine if treatment with Haelan (fermented soy product) can decrease the severity of poor appetite measured using a visual analog scale (VAS) of 0 to 100 mm (0 mm = best, 100 mm = worst) at week 4 +/- 5 days. * To determine if treatment with Haelan can decrease the severity of nausea, fatigue, and improve patients' overall sense of well being measured using a VAS of 0 to 100 mm (0 mm = best, 100 mm = worst) at week 4 +/- 5 days. * To determine if treatment with Haelan can increase patient's calorie intake, albumin, pre-albumin, anthropometric measure, lean body mass (measured by bio-impedence analysis), and weight at week 4+/- 5 days. * To determine if treatment with Haelan can decrease patient's Functional assessment of anorexia/cachexia therapy subscales or (FAACT) and the Functional Assessment of Chronic Illness Therapy with fatigue subscales (FACIT-F) at week 4+/- 5 days. * To assess the feasibility of accrual, and adherence to the Haelan consumption. Secondary: * Determine the plasma isoflavone activity, 12-MTA and 13-MTA of these patients. * Correlate the biologic modulation of peripheral blood lymphocyte NF-kB by Haelan with primary outcome in these patients. * To determine if treatment with Haelan can increase patient's functional status at week 4+/- 5 days.

Conditions

  • Anorexia
  • Weight Loss
  • Cachexia

Interventions

  • HaelanDrug

    4 oz orally twice daily for 8 Weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Severity of Poor Appetite Following Treatment With Haelan (Fermented Soy Product)Time frame: Baseline and Week 4 +/- 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • U.T.M.D. Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.